B. Cherrier, F. Gouin, M. F. Heymann, J. P. Thiéry, F. Rédini et al., A New Experimental Rat Model of Osteosarcoma Established by Intrafemoral Tumor Cell Inoculation, Useful for Biology and Therapy Investigations, Tumor Biology, vol.47, issue.3, pp.121-130, 2005.
DOI : 10.1006/bbrc.1999.0997

J. L. Ordóñez, A. T. Amaral, A. M. Carcaboso, D. Herrero-martín, M. et al., The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin, pp.26027-26040, 2015.

D. Heymann, B. Ory, F. Blanchard, M. F. Heymann, P. Coipeau et al., Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005.
DOI : 10.1016/j.bone.2005.02.020

E. Grimaud, C. Damiens, A. V. Rousselle, N. Passuti, D. Heymann et al., Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma, Histol. Histopathol, pp.17-1103, 2002.

Z. F. Zhou, T. W. Sun, F. Chen, D. Q. Zuo, H. S. Wang et al., Calcium phosphate-phosphorylated adenosine hybrid microspheres for anti-osteosarcoma drug delivery and osteogenic differentiation, Biomaterials, vol.121, pp.1-14, 2017.
DOI : 10.1016/j.biomaterials.2016.12.031

A. E. Grigoriadis, K. Schellander, Z. Q. Wang, and E. F. Wagner, Osteoblasts are target cells for transformation in c-fos transgenic mice, The Journal of Cell Biology, vol.122, issue.3, pp.685-701, 1993.
DOI : 10.1083/jcb.122.3.685

Z. Duan, Y. Gao, J. Shen, E. Choy, G. Cote et al., Hornicek, miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo, Mol. Oncol, pp.11-151, 2017.

D. Meier, S. M. Botter, C. Campanile, B. Robl, S. Gräfe et al., and in intratibial mouse models, International Journal of Cancer, vol.40, issue.7, pp.1680-1692, 2017.
DOI : 10.1002/lsm.20662

I. J. Fidler and M. L. Kripke, Metastasis results from preexisting variant cells within a malignant tumor, Science, vol.197, issue.4306, pp.893-895, 1977.
DOI : 10.1126/science.887927

T. Asai, T. Ueda, K. Itoh, K. Yoshioka, Y. Aoki et al., Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung, International Journal of Cancer, vol.199, issue.3, pp.418-422, 1998.
DOI : 10.1111/j.1349-7006.1988.tb00027.x

M. J. Arlt, I. J. Banke, D. K. Walters, G. J. Puskas, P. Steinmann et al., LacZ transgene expression in the subcutaneous Dunn/LM8 osteosarcoma mouse model allows for the identification of micrometastasis, Journal of Orthopaedic Research, vol.26, issue.6, pp.29-938, 2011.
DOI : 10.1089/dna.2006.0531

P. W. Ho, A. Godadia, M. R. Russell, A. M. Chalk, K. M. Milley et al., Knockdown of PTHR1 in osteosarcoma cells decreases invasion and growth and increases tumor differentiation in vivo, Oncogene, vol.268, issue.22, pp.2922-2933, 2015.
DOI : 10.1038/ng1651

E. K. Baker, S. Taylor, A. Gupte, P. P. Sharp, M. Walia et al., BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells, Scientific Reports, vol.287, issue.1, 2015.
DOI : 10.1074/jbc.M111.306019

URL : http://www.nature.com/articles/srep10120.pdf

S. Bhattacharya, A. M. Chalk, A. L. Ng, T. J. Martin, A. C. Zannettino et al., Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death, Oncogene, vol.14, issue.40, pp.5282-5294, 2016.
DOI : 10.1016/j.devcel.2008.03.012

M. K. Walia, P. M. Ho, S. Taylor, A. J. Ng, A. Gupte et al., Author response, eLife, vol.34, pp.5-2016
DOI : 10.7554/eLife.13446.040

P. Techavichit, Y. Gao, L. Kurenbekova, R. Shuck, L. A. Donehower et al., Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential, BMC Cancer, vol.132, issue.7, p.16, 2016.
DOI : 10.1002/ijc.27745

URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-016-2909-6?site=bmccancer.biomedcentral.com

B. A. Teicher, R. G. Bagley, C. Rouleau, A. Kruger, Y. Ren et al., Characteristics of human Ewing/PNET sarcoma models, Ann. Saudi Med, pp.31-174, 2011.
DOI : 10.4103/0256-4947.78206

URL : http://doi.org/10.4103/0256-4947.78206

C. Rouleau, D. A. Gianolio, R. Smale, S. D. Roth, R. Krumbholz et al., Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies, Molecular Cancer Therapeutics, vol.14, issue.9, pp.2081-2089, 2015.
DOI : 10.1158/1535-7163.MCT-15-0312

URL : http://mct.aacrjournals.org/content/molcanther/14/9/2081.full.pdf

C. Ren, T. Ren, K. Yang, S. Wang, X. Bao et al., Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing???s sarcoma through the PI3K/Akt pathway, Journal of Experimental & Clinical Cancer Research, vol.12, issue.1, p.44, 2016.
DOI : 10.1158/0008-5472.CAN-08-4041

T. Hensel, C. Giorgi, O. Schmidt, J. Calzada-wack, F. Neff et al., Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma, Oncotarget, vol.7, issue.2, pp.1451-1463, 2016.
DOI : 10.18632/oncotarget.6385

URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=6385&path%5B%5D=17488

A. L. Kennedy, M. Vallurupalli, L. Chen, B. Crompton, G. Cowley et al., Stegmaier, Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1, Oncotarget, vol.6, pp.30178-30193, 2015.
DOI : 10.18632/oncotarget.4903

URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=4903&path%5B%5D=13227

J. Li, L. Wang, Z. Liu, C. Zu, F. Xing et al., MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells <i>in vivo</i> and <i>in vitro</i> by directly targeting SOX9, Oncotarget, vol.6, issue.28, pp.26216-26229, 2015.
DOI : 10.18632/oncotarget.4460

Z. Q. Wang, A. E. Grigoriadis, U. Möhle-steinlein, and E. F. Wagner, A novel target cell for c-fos-induced oncogenesis: development of chondrogenic tumours in embryonic stem cell chimeras, EMBO J, vol.110, pp.2437-2450, 1991.

G. T. Liu, Y. L. Huang, H. E. Tzeng, C. H. Tsai, S. W. Wang et al., CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells, Cancer Letters, vol.357, issue.2, pp.476-487, 2015.
DOI : 10.1016/j.canlet.2014.11.015

X. Sun, C. Charbonneau, L. Wei, Q. Chen, and R. M. , miR-181a Targets RGS16 to Promote Chondrosarcoma Growth, Angiogenesis, and Metastasis, Molecular Cancer Research, vol.13, issue.9, pp.1347-1357, 2015.
DOI : 10.1158/1541-7786.MCR-14-0697

URL : http://mcr.aacrjournals.org/content/molcanres/13/9/1347.full.pdf

C. H. Chen, C. J. Li, I. C. Tai, X. H. Lin, H. K. Hsu et al., The fractionated toona sinensis leaf extract induces apoptosis of human osteosarcoma cells and inhibits tumour growth in a murine xenograft model, Integr. Cancer Ther, pp.16-397, 2017.

A. J. Hesketh, C. Maloney, C. A. Behr, M. C. Edelman, R. D. Glick et al., The Macrophage Inhibitor CNI-1493 Blocks Metastasis in a Mouse Model of Ewing Sarcoma through Inhibition of Extravasation, PLOS ONE, vol.2, issue.2, p.145197, 2015.
DOI : 10.1371/journal.pone.0145197.s005

C. L. Osgood, N. Maloney, C. G. Kidd, S. Kitchen-goosen, L. Segars et al., Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor, Clinical Cancer Research, vol.22, issue.16, pp.4105-4118, 2016.
DOI : 10.1158/1078-0432.CCR-15-2624

J. C. Chen, C. Y. Lin, Y. C. Fong, C. J. Hsu, C. H. Tsai et al., Amphiregulin enhances alpha6beta1 integrin expression and cell motility in human chondrosarcoma cells through Ras/Raf/MEK/ERK/AP-1 pathway, AP-1 pathway, pp.11434-11446, 2015.
DOI : 10.18632/oncotarget.3397

URL : http://europepmc.org/articles/pmc4484467?pdf=render

B. Gobin, M. Baud-'huin, F. Lamoureux, B. Ory, C. Charrier et al., BYL719, a new ??-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma, International Journal of Cancer, vol.70, issue.Supp 1, pp.784-796, 2015.
DOI : 10.1158/0008-5472.CAN-09-4172

URL : https://hal.archives-ouvertes.fr/inserm-01644799

F. Lamoureux, M. Baud-'huin, L. Rodriguez-calleja, C. Jacques, M. Berreur et al., Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle, Nature Communications, vol.128, issue.1, p.511, 2014.
DOI : 10.1002/ijc.25776

URL : http://www.nature.com/articles/ncomms4511.pdf

C. Jacques, F. Lamoureux, M. Baud-'huin, L. Rodriguez-calleja, T. Quillard et al., Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1, pp.24125-24140, 2016.

Y. Tome, H. Kimura, N. Sugimoto, H. Tsuchiya, F. Kanaya et al., The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing alphanubeta3 integrin in chick embryo and nude mouse models, Oncotarget, vol.7, pp.87031-87036, 2016.

M. C. Scott, H. Tomiyasu, J. R. Garbe, I. Cornax, C. Amaya et al., Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior, Disease Models & Mechanisms, vol.9, issue.12, pp.1435-1444, 2016.
DOI : 10.1242/dmm.026849

S. Shimozaki, N. Yamamoto, T. Domoto, H. Nishida, K. Hayashi et al., Efficacy of glycogen synthase kinase- 3beta. targeting against osteosarcoma via activation of beta-catenin, Oncotarget, vol.7, pp.77038-77051, 2016.

D. G. Kashima, C. Zandueta, N. Perurena, D. P. Thomas, A. Sunters et al., Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1, Oncogene, vol.35, pp.2852-2861, 2016.

V. Crenn, K. Biteau, J. Maiaud, C. Dumars, R. Guiho et al., Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling, Am. J. Cancer Res, vol.7, pp.2333-2349, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01680800

S. Westrom, T. B. Bønsdorff, N. Abbas, Ø. S. Bruland, T. J. Jonasdottir et al., Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma, PLOS ONE, vol.18, issue.2, pp.11-0165382, 2016.
DOI : 10.1371/journal.pone.0165382.g006

F. Lamoureux, P. Richard, Y. Wittrant, S. Battaglia, P. Pilet et al., Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the Vicious Cycle between Tumor Cell Proliferation and Bone Resorption, Cancer Research, vol.67, issue.15, pp.7308-7318, 2007.
DOI : 10.1158/0008-5472.CAN-06-4130

D. Monderer, A. Luseau, A. Bellec, E. David, S. Ponsolle et al., New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance, Lab. Investig, pp.93-100, 2013.

F. Gouin, B. Ory, F. Rédini, and D. Heymann, Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival, International Journal of Cancer, vol.43, issue.5, pp.980-984, 2006.
DOI : 10.1016/S1470-2045(04)01710-3

C. R. Walkley, R. Qudsi, V. G. Sankaran, J. A. Perry, M. Gostissa et al., Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease, Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease, pp.1662-1676, 2008.
DOI : 10.1101/gad.1656808

A. J. Mutsaers, A. J. Ng, E. K. Baker, M. R. Russell, A. M. Chalk et al., Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA, Bone, vol.55, issue.1, pp.166-167, 2013.
DOI : 10.1016/j.bone.2013.02.016

E. Stewart, R. Goshorn, C. Bradley, L. M. Griffiths, C. Benavente et al., Targeting the DNA Repair Pathway in Ewing Sarcoma, Cell Reports, vol.9, issue.3, pp.829-841, 2014.
DOI : 10.1016/j.celrep.2014.09.028

E. Stewart, S. Federico, A. Karlstrom, A. Shelat, A. Sablauer et al., The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities, Developmental Biology, vol.411, issue.2, pp.411-287, 2016.
DOI : 10.1016/j.ydbio.2015.03.001

T. Murakami, K. Igarashi, K. Kawaguchi, T. Kiyuna, Y. Zhang et al., Journal of Bone Oncology, vol.12, pp.7-13, 2018.

, Tumour-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug, Oncotarget, vol.7, pp.12783-12790, 2016.

S. D. Goldstein, M. Trucco, W. Bautista-guzman, M. Hayashi, and D. M. Loeb, A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model, Oncotarget, vol.7, issue.16, pp.21114-21123, 2016.
DOI : 10.18632/oncotarget.8522

S. R. Ambati, J. H. Shieh, B. Pera, E. C. Lopes, A. Chaudhry et al., BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models, Oncotarget, vol.7, issue.28, pp.43062-43075, 2016.
DOI : 10.18632/oncotarget.9657

URL : http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=9657&path%5B%5D=30246

S. D. Berman, E. Calo, A. S. Landman, P. S. Danielian, E. S. Miller et al., Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage Proc. Natl. Acad. Sci. USA 105, pp.11851-11856, 2008.

L. H. Chan, W. Wang, W. Yeung, Y. Deng, P. Yuan et al., Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression, Oncogene, vol.56, issue.40, pp.4857-4866, 2014.
DOI : 10.1111/j.1048-891x.2004.014314.x

C. E. De-andrea, J. F. Zhu, H. Jin, J. V. Bovee, and K. B. Jones, Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency, J. Pathol, pp.236-210, 2015.

N. Entz-werle, P. Choquet, A. Neuville, S. Kuchler-bopp, F. Clauss et al., Targeted Apc;Twist Double-Mutant Mice: A New Model of Spontaneous Osteosarcoma That Mimics the Human Disease, Translational Oncology, vol.3, issue.6, pp.344-353, 2010.
DOI : 10.1593/tlo.10169

URL : https://hal.archives-ouvertes.fr/hal-00591470

A. E. Grigoriadis, K. Schellander, Z. Q. Wang, and E. F. Wagner, Osteoblasts are target cells for transformation in c-fos transgenic mice, The Journal of Cell Biology, vol.122, issue.3, pp.685-701, 1993.
DOI : 10.1083/jcb.122.3.685

S. A. Hansen, M. L. Hart, S. Busi, T. Parker, A. et al., -knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis, Disease Models & Mechanisms, vol.4, issue.10, pp.1139-1146, 2016.
DOI : 10.1093/carcin/bgs238

P. P. Lin, M. K. Pandey, F. Jin, S. Xiong, M. Deavers et al., EWS- FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model, Cancer Res, pp.68-8968, 2008.

Y. Lu, S. Gitelis, G. Lei, M. Ding, C. Maki et al., Research findings working with the p53 and Rb1 targeted osteosarcoma mouse model, pp.34-244, 2014.

A. J. Mutsaers, A. J. Ng, E. K. Baker, M. R. Russell, A. M. Chalk et al., Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA, Bone, vol.55, issue.1, pp.166-178, 2013.
DOI : 10.1016/j.bone.2013.02.016

S. D. Molyneux, M. A. Di, A. G. Grappa, T. D. Beristain, D. Mckee et al., Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice, Journal of Clinical Investigation, vol.120, issue.9, pp.3310-3325, 2010.
DOI : 10.1172/JCI42391DS1

T. J. Tao, M. M. Jiang, L. Jiang, J. S. Salvo, H. C. Zeng et al., Notch Activation as a Driver of Osteogenic Sarcoma, Cancer Cell, vol.26, issue.3, pp.390-401, 2014.
DOI : 10.1016/j.ccr.2014.07.023

E. C. Torchia, K. Boyd, J. E. Rehg, C. Qu, and S. J. Baker, EWS/FLI-1 Induces Rapid Onset of Myeloid/Erythroid Leukemia in Mice, Molecular and Cellular Biology, vol.27, issue.22, pp.7918-7934, 2007.
DOI : 10.1128/MCB.00099-07

C. R. Walkley, R. Qudsi, V. G. Sankaran, J. A. Perry, M. Gostissa et al., Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease, Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease, pp.1662-1676, 2008.
DOI : 10.1101/gad.1656808

T. Quist, H. Jin, J. F. Zhu, K. Smith-fry, M. R. Capecchi et al., The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse, Oncogene, vol.16, issue.32, pp.4278-4284, 2015.
DOI : 10.1158/1078-0432.CCR-09-2499

T. Z. Minas, D. Surdez, T. Javaheri, M. Tanaka, M. Howarth et al., Oncotarget, vol.8, pp.34141-34163, 2017.

J. M. Fenger, R. D. Roberts, O. H. Iwenofu, M. D. Bear, X. Zhang et al., MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines, BMC Cancer, vol.69, issue.1, p.784, 2016.
DOI : 10.1158/0008-5472.CAN-08-1648

N. J. Mason, J. S. Gnanandarajah, J. B. Engiles, F. Gray, D. Laughlin et al., Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma, Clinical Cancer Research, vol.22, issue.17, pp.4380-4390, 2016.
DOI : 10.1158/1078-0432.CCR-16-0088

C. Khanna, T. M. Fan, R. Gorlick, L. J. Helman, E. S. Kleinerman et al., Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma, Clinical Cancer Research, vol.20, issue.16, pp.4200-4209, 2014.
DOI : 10.1158/1078-0432.CCR-13-2574

A. V. Ng, K. M. Walia, M. F. Smeets, A. J. Mutsaers, N. A. Sims et al., The DNA Helicase Recql4 Is Required for Normal Osteoblast Expansion and Osteosarcoma Formation, PLOS Genetics, vol.106, issue.4, p.1005160, 2015.
DOI : 10.1371/journal.pgen.1005160.s009

C. Jacques, Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitations, Journal of Bone Oncology, vol.12, pp.7-13, 2018.
DOI : 10.1016/j.jbo.2018.02.004

URL : https://hal.archives-ouvertes.fr/inserm-01814330